Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan/hydrochlorothiazide dose escalation study in uncontrolled hypertension
2005-002442-19Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of telmisartan and hydrochlorothiazide in essential hypertension and resistant hypertension (RH) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in seated trough diastolic blood pressure. Started Jun 2005; status: completed.
02
Drugs
telmisartanhydrochlorothiazide
03
Conditions
essential hypertensionresistant hypertension (RH)
Beyond the preview
Go deeper on 2005-002442-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002442-19.